AVENUE SOLUTIONS for IOVANCE BIOTHERAPEUTICS, INC.
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to H.R. 5376, Inflation Reduction Act of 2022 (now PL 117-169) and implementation; Issues related to the Continuing Resolution, H.R. 6833; Education around tumor infiltrating lymphocytes (TIL) cancer therapies; S. 3700/H.R. 6833, Affordable Insulin Now Act; Issues related to reauthorization of FDA user fee bills (H.R. 7667, Food and Drug Amendments of 2022; S. 4348 Food and Drug Administration Safety and Landmark Advancements Act of 2022 (FDSLA Act of 2022)), including accelerated approval and reimportation; Issues related to the Public Health Emergency; H.R. 5585, Advanced Research Project Agency-Health (ARPA-H) Act; Issues related to the White House Cancer Moonshot initiative; Issues related to accelerated approval; Issues related to the FY 2023 President's Budget; CMS Medicare Hospital Inpatient Prospective Payment System (IPPS) and Long-Term Care Hospital (LTCH) Rates Proposed Rule for FY 2023; Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act
| Lobbyist | Covered position, as disclosed |
|---|---|
| ELIZABETH MACDONALD BARNETT | — |
| TRACY SPICER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.